Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody- based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies' bispecific ADC development programs. "We have been very impressed with ...

- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immu ...